Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection Charlotte Billiet, MD, Stéphanie.

Slides:

Advertisements

Similar presentations

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

SC17.02 Lung Cancer in China: Challenges and Perspectives

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Preoperative Exercise Vo2 Measurement for Lung Resection Candidates: Results of Cancer and Leukemia Group B Protocol 9238 Gregory M. Loewen, DO, Dorothy.

OA Mediastinal Staging by Videomediastinoscopy in Clinical N1 Non-Small Cell Lung Cancer: a Prospective Multicenter Study H. Decaluwe, C. Dooms,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab Monica Khunger, MD Journal of Thoracic.

Impact of Lung Function Changes After Induction Radiochemotherapy on Resected T4 Non-Small Cell Lung Cancer Outcome Jean Perentes, MD, PhD, Sabina Bopp,

Phase II Trial of SBRT for Stage I NSCLC: Survival, Local Control, and Lung Function at 36 Months Arturo Navarro-Martin, MD, Samantha Aso, MD, Jon Cacicedo,

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma Nader Abedallaa, MD, Lise Tremblay, MD, Charlotte.

Nikolaas De Maeyer, MD, Walter De Wever, MD, PhD, Christophe M

Esophageal Ultrasound-Controlled Fine Needle Aspiration for Staging of Mediastinal Lymph Nodes in Patients with Resectable Lung Cancer: Do We Always See.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Regional Emphysema Score Predicting Overall Survival, Quality of Life, and Pulmonary Function Recovery in Early-Stage Lung Cancer Patients Jie Dai, PhD,

A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non–Small Cell Lung Cancer Naoyoshi Yamamoto, MD,

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Clinical outcomes and changes in lung function after segmentectomy versus lobectomy for lung cancer cases Bo Deng, MD, PhD, Stephen D. Cassivi, MD, Mariza.

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Relationship Between Functional Preservation after Segmentectomy and Volume- Reduction Effects after Lobectomy in Stage I Non-small Cell Lung Cancer Patients.

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Benjamin Besse, Johan.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

PD5-1-7: Time trends in nodal CT volume and nodal motion during radiotherapy for patients with stage III non-small cell lung cancer Geert Bosmans, Angela.

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Mark F. Berry, MD, Chi-Fu Jeffrey.

A1-02: A need to standardize post-operative radiotherapy (PORT) fields used for non- small cell lung cancer (NSCLC): analysis of an international dummy-run.

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

It’s All in the “Swerve of the Curve”

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

A Phase I Study of Gefitinib with Concurrent Dose-Escalated Weekly Docetaxel and Conformal Three-Dimensional Thoracic Radiation Followed by Consolidative.

Predictors of Surgery and Consult with an Oncologist for Adjuvant Chemotherapy in Early Stage NSCLC Patients in Alberta, Canada Marcy Winget, PhD, Jennifer.

Large Bronchopleural Fistula After Surgical Resection: Secret to Success Isabelle Delanote, MD, Werner Budts, MD, PhD, Paul De Leyn, MD, PhD, Christophe.

Survival after Trimodality Treatment for Superior Sulcus and Central T4 Non-small Cell Lung Cancer Paul De Leyn, MD, PhD, Johan Vansteenkiste, MD, PhD,

Patterns of Locoregional Relapses in Patients with Contemporarily Staged Stage III-N2 NSCLC Treated with Induction Chemotherapy and Resection: Implications.

Predicted Versus Observed FEV1 and Dlco After Major Lung Resection: A Prospective Evaluation at Different Postoperative Periods Alessandro Brunelli,

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

A Review of First-Line Treatment for Small-cell Lung Cancer

The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients Gokoulakrichenane Loganadane, MD, Lizza Hendriks, MD, PhD, Cécile.

Robert Comis, MD, The Passing of a “Lung Man”

Presentation transcript:

Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and Resection Charlotte Billiet, MD, Stéphanie Peeters, MD, PhD, Herbert Decaluwé, MD, Johan Vansteenkiste, MD, PhD, Christophe Dooms, MD, PhD, Christophe M. Deroose, MD, PhD, Marc Hendrikx, MD, PhD, Paul De Leyn, MD, PhD, Paul Bulens, MD, Rezaul Karim, MD, Cécile Le Péchoux, MD, Jeroen Mebis, MD, PhD, Dirk De Ruysscher, MD, PhD Journal of Thoracic Oncology Volume 11, Issue 11, Pages 1940-1953 (November 2016) DOI: 10.1016/j.jtho.2016.06.018 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Patient inclusion algorithm. PORT, postoperative radiotherapy. Journal of Thoracic Oncology 2016 11, 1940-1953DOI: (10.1016/j.jtho.2016.06.018) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Changes compared with baseline of clinical parameters (dyspnea and cough) and lung function parameters (forced expiratory volume in 1 second [FEV1] and diffusing capacity of the lung for carbon monoxide [Dlco]) in follow-up in the postoperative radiotherapy (PORT) versus non-PORT groups (per-protocol analysis). Acute post-RT means 3 months or less after start of radiotherapy RT, and late post-RT means 12 months or less after start RT. Journal of Thoracic Oncology 2016 11, 1940-1953DOI: (10.1016/j.jtho.2016.06.018) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions